stockrow
Friday 6 November 2026
Export TNGX’s income statement to Excel — free account
Tango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
21.50
0.63
+3.02%
Follow TNGX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 4 | 3 |
+8 more TTM periods Free account |
| (21.34%) | (38.42%) | (37.23%) | (51.65%) | ||
| (18.86%) | (30.20%) | (28.41%) | (35.74%) | ||
ROIC |
(808.35%) | (629.60%) | (2,661.91%) | (1,015.30%) | |
Return on Tangible Assets |
(12.16%) | (27.90%) | (29.97%) | (65.83%) | |
Average Days of Receivables |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.96) | (0.99) | (1.20) | (1.32) | |
Free Cash Flow |
(144.25) | (142.54) | (139.93) | (146.76) | |
Capital Expenditures |
(0.35) | (0.99) | (1.05) | (0.95) | |
| Other line items | |||||
Cash ROIC |
(7.08%) | (18.48%) | (20.29%) | (46.85%) | |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 211.86% | 201.50% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 66.54% | 64.41% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 42.37% | 41.97% | |
Operating CF/Net income |
1.16 | 1.32 | 1.37 | 1.45 | |
Depreciation/Fixed assets |
(0.24) | (0.16) | (0.06) | (0.05) | |
Capex/Depreciation |
0.24 | 0.95 | 2.57 | 2.68 | |
Revenue per Share |
0.00 | 0.00 | 0.54 | 0.60 | |
Operating CF per Share |
(0.96) | (0.99) | (1.20) | (1.31) | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.02 | 0.01 |
Columns are period end dates